1 Centre for Heart Lung Innovation, St. Paul's Hospital.
2 Division of Pulmonary Medicine, Department of Medicine, College of Medicine, King Saud University, Riyadh, Saudi Arabia.
Am J Respir Crit Care Med. 2019 May 15;199(10):1205-1213. doi: 10.1164/rccm.201806-1135OC.
Lung dysbiosis promotes airway inflammation and decreased local immunity, potentially playing a role in the pathogenesis of acute exacerbations of chronic obstructive pulmonary disease (AECOPD). We sought to determine the relationship between sputum microbiome at the time of AECOPD hospitalization and 1-year mortality in a COPD cohort. We used sputum samples from 102 patients hospitalized because of AECOPD. All subjects were followed for 1 year after discharge. The microbiome profile was assessed through sequencing of 16S rRNA gene. Microbiome analyses were performed according to 1-year mortality status. To investigate the effect of α-diversity measures and taxon features on time to death, we applied Cox proportional hazards regression models and obtained hazard ratios (HRs) associated with these variables. We observed significantly lower values of α-diversity (richness, Shannon index, evenness, and Faith's Phylogenetic Diversity) among nonsurvivors ( = 19, 18.6%) than survivors ( = 83, 81.4%). β-Diversity analysis also demonstrated significant differences between both groups (adjusted permutational multivariate ANOVA, = 0.010). The survivors had a higher relative abundance of ; in contrast, nonsurvivors had a higher abundance of . The adjusted HRs for 1-year mortality increased significantly with decreasing α-diversity. We also observed lower survival among patients in whom sputum samples were negative for (HR, 13.5; 95% confidence interval, 4.2-43.9; < 0.001) or positive for (HR, 7.3; 95% confidence interval, 1.6-33.2; = 0.01). The microbiome profile of sputum in AECOPD is associated with 1-year mortality and may be used to identify subjects with a poor prognosis at the time of hospitalization.
肺菌群失调促进气道炎症和局部免疫功能下降,可能在慢性阻塞性肺疾病(COPD)急性加重(AECOPD)的发病机制中发挥作用。我们旨在确定 AECOPD 住院期间痰液微生物组与 COPD 患者 1 年死亡率之间的关系。我们使用了 102 例因 AECOPD 住院的患者的痰液样本。所有患者在出院后随访 1 年。通过 16S rRNA 基因测序评估微生物组谱。根据 1 年死亡率状态进行微生物组分析。为了研究α多样性措施和分类群特征对死亡时间的影响,我们应用 Cox 比例风险回归模型并获得与这些变量相关的风险比(HRs)。我们观察到,在非幸存者( = 19,18.6%)中,α多样性(丰富度、香农指数、均匀度和 Faith 的系统发育多样性)值显著低于幸存者( = 83,81.4%)。β多样性分析也显示两组之间存在显著差异(调整后的置换多元方差分析, = 0.010)。幸存者的相对丰度较高,而非幸存者的相对丰度较高。1 年死亡率的调整 HR 随着α多样性的降低而显著增加。我们还观察到,在痰液样本中阴性的患者中,生存率较低(HR,13.5;95%置信区间,4.2-43.9; < 0.001)或阳性(HR,7.3;95%置信区间,1.6-33.2; = 0.01)的患者。AECOPD 痰液微生物组与 1 年死亡率相关,可用于识别住院时预后不良的患者。